[HTML][HTML] Cost-effectiveness of direct oral anticoagulant vs. warfarin among atrial fibrillation patients with intermediate stroke risk
Background: Several studies have shown the cost-effectiveness of direct oral anticoagulants
(DOACs), compared with warfarin, to prevent atrial fibrillation (AF) related complications …
(DOACs), compared with warfarin, to prevent atrial fibrillation (AF) related complications …
Cost‐effectiveness analysis of dabigatran, rivaroxaban and warfarin in the prevention of stroke in patients with atrial fibrillation in China
H Wei, C Cui, X Cui, Y Liu, D Li - BMC Health Services Research, 2021 - Springer
Background and objective To evaluate the cost-effectiveness of new anticoagulants and
warfarin in the prevention of stroke in Chinese patients with atrial fibrillation (AF). Methods …
warfarin in the prevention of stroke in Chinese patients with atrial fibrillation (AF). Methods …
[HTML][HTML] Cost-effectiveness analysis of oral anticoagulants in stroke prevention among patients with atrial fibrillation in Taiwan
CT Liao, MC Lee, ZC Chen, LJE Ku… - Acta Cardiologica …, 2020 - ncbi.nlm.nih.gov
Background Non-vitamin K oral antagonist anticoagulants (NOACs) have been widely used
in stroke prevention in atrial fibrillation (SPAF). The aim of this study was to compare the …
in stroke prevention in atrial fibrillation (SPAF). The aim of this study was to compare the …
[HTML][HTML] Cost-Effectiveness analysis of direct-acting oral anticoagulants for stroke prevention in Thai patients with Non-Valvular atrial fibrillation and a high risk of …
T Rattanachotphanit, C Limwattananon… - …, 2019 - Springer
Objective The objective of this study was to assess the cost effectiveness of direct-acting oral
anticoagulants for stroke prevention in Thai patients with non-valvular atrial fibrillation and a …
anticoagulants for stroke prevention in Thai patients with non-valvular atrial fibrillation and a …
Cost effectiveness of novel oral anticoagulants for stroke prevention in atrial fibrillation depending on the quality of warfarin anticoagulation control
A Janzic, M Kos - Pharmacoeconomics, 2015 - Springer
Background Vitamin K antagonists, such as warfarin, are standard treatments for stroke
prophylaxis in patients with atrial fibrillation. Patient outcomes depend on quality of warfarin …
prophylaxis in patients with atrial fibrillation. Patient outcomes depend on quality of warfarin …
Effectiveness and safety of direct oral anticoagulants and warfarin, stratified by stroke risk in patients with atrial fibrillation
I Hernandez, Y Zhang, S Saba - The American journal of cardiology, 2018 - Elsevier
The objective of the study was to examine how the comparative effectiveness and safety of
direct oral anticoagulants (DOACs) and warfarin differ across subgroups of patients with …
direct oral anticoagulants (DOACs) and warfarin differ across subgroups of patients with …
Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense …
Background Clinical trials have demonstrated that direct oral anticoagulants (DOACs) are at
least non-inferior to warfarin in reducing the risk of stroke/systemic embolism (SE) among …
least non-inferior to warfarin in reducing the risk of stroke/systemic embolism (SE) among …
Medical costs of oral anticoagulants vs warfarin for atrial fibrillation patients with different stroke risks
S Deitelzweig, A Amin, Y Jing, D Makenbaeva… - Cardiology and …, 2013 - Springer
Abstract Introduction The Apixaban for the Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE), Randomized Evaluation of Long-term …
Events in Atrial Fibrillation (ARISTOTLE), Randomized Evaluation of Long-term …
A real-world observational study of hospitalization and health care costs among nonvalvular atrial fibrillation patients prescribed oral anticoagulants in the US …
A Amin, A Keshishian, J Trocio, O Dina, H Le… - Journal of Managed …, 2018 - jmcp.org
This article has been corrected. Please see J Manag Care Spec Pharm, 2020; 26 (5): 682
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
A real-world observational study of hospitalization and health care costs among nonvalvular atrial fibrillation patients prescribed oral anticoagulants in the US …
A Amin, A Keshishian, J Trocio, O Dina, H Le… - Journal of Managed …, 2020 - jmcp.org
This article has been corrected. Please see J Manag Care Spec Pharm, 2020; 26 (5): 682
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …
BACKGROUND: Clinical trials have shown that direct oral anticoagulants (DOACs) …